UCLA Health

uclahealth.org

For more than half a century, UCLA Health has provided the best in healthcare and the latest in medical technology to the people of Los Angeles and throughout the world. Comprised of Ronald Reagan UCLA Medical Center, UCLA Medical Center Santa Monica, Resnick Neuropsychiatric Hospital at UCLA, UCLA Mattel Children's Hospital, and the UCLA Medical Group with its wide-reaching system of primary-care and specialty-care offices throughout the region, UCLA Health is among the most comprehensive and advanced healthcare systems in the world.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDTECH

BIOTECH START-UP AANIKA BIOSCIENCES LANDS INITIAL $12M FUNDING FOR CUTTING-EDGE FOOD TRACING TECHNOLOGY

Aanika Biosciences | December 01, 2021

news image

Biotech start-up Aanika Biosciences today announced the initial closing of its $12 million Series A round, led by Jon Cholak of Adit Ventures along with existing investors Draper Associates and SOSV. The investment will help scale the company’s food tracing technology platform, advance research and expand its Brooklyn food safety and manufacturing facility to approximately 30,000 square feet. Aanika's proprietary technology is designed to accelerate the speed and accurac...

Read More

INDUSTRIAL IMPACT

BEIGENE ANNOUNCES APPROVAL FOR BRUKINSA (ZANUBRUTINIB) BY SWISSMEDIC FOR TREATMENT OF ADULT PATIENTS WITH WALDENSTRÖMS MACROGLOBULINEMIA

BeiGene | February 18, 2022

news image

BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines, today announced that BeiGene’s BTK inhibitor BRUKINSA received approval from Swissmedic for the treatment of adult patients with Waldenström’s macroglobulinemia who have received at least one prior line of therapy, or for treatment-naïve patients who are not suited for standard chemo-immunotherapy. BRUKINSA had previously been granted orphan drug status. ...

Read More

INDUSTRIAL IMPACT

VERSANT VENTURES COLLABORATES WITH ABCELLERA TO ACCELERATE DRUG DEVELOPMENT FOR ITS PORTFOLIO OF BIOTECH COMPANIES

AbCellera and Versant Ventures | July 28, 2022

news image

AbCellera and Versant Ventures announced a multi-year collaboration to discover therapeutic antibodies for multiple targets selected by Versant’s portfolio of biologics-focused biotechs. Versant and AbCellera already have enabled three of the firm’s stealth-stage companies under previous partnerships. Under the terms of the deal, Versant portfolio companies will have rights to develop and commercialize the resulting therapeutic antibodies. AbCellera will receive resear...

Read More

CELL AND GENE THERAPY

INTRAVACC ANNOUNCES ADDITIONAL FAVORABLE PRECLINICAL AND TOXICOLOGY DATA FOR AVACC 10®, AN INTRANASAL SARS-COV-2 CANDIDATE VACCINE

Intravacc | September 12, 2022

news image

Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced additional favorable preclinical and toxicology data for Avacc 10®, the company's SARS-CoV-2 intranasal candidate vaccine. These results demonstrate a reduction in upper respiratory tract viral load, broad cross protection against circulating variants of concern. and a good safety profile, allowing progression towards a phase I clinical study. ...

Read More
news image

MEDTECH

BIOTECH START-UP AANIKA BIOSCIENCES LANDS INITIAL $12M FUNDING FOR CUTTING-EDGE FOOD TRACING TECHNOLOGY

Aanika Biosciences | December 01, 2021

Biotech start-up Aanika Biosciences today announced the initial closing of its $12 million Series A round, led by Jon Cholak of Adit Ventures along with existing investors Draper Associates and SOSV. The investment will help scale the company’s food tracing technology platform, advance research and expand its Brooklyn food safety and manufacturing facility to approximately 30,000 square feet. Aanika's proprietary technology is designed to accelerate the speed and accurac...

Read More
news image

INDUSTRIAL IMPACT

BEIGENE ANNOUNCES APPROVAL FOR BRUKINSA (ZANUBRUTINIB) BY SWISSMEDIC FOR TREATMENT OF ADULT PATIENTS WITH WALDENSTRÖMS MACROGLOBULINEMIA

BeiGene | February 18, 2022

BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines, today announced that BeiGene’s BTK inhibitor BRUKINSA received approval from Swissmedic for the treatment of adult patients with Waldenström’s macroglobulinemia who have received at least one prior line of therapy, or for treatment-naïve patients who are not suited for standard chemo-immunotherapy. BRUKINSA had previously been granted orphan drug status. ...

Read More
news image

INDUSTRIAL IMPACT

VERSANT VENTURES COLLABORATES WITH ABCELLERA TO ACCELERATE DRUG DEVELOPMENT FOR ITS PORTFOLIO OF BIOTECH COMPANIES

AbCellera and Versant Ventures | July 28, 2022

AbCellera and Versant Ventures announced a multi-year collaboration to discover therapeutic antibodies for multiple targets selected by Versant’s portfolio of biologics-focused biotechs. Versant and AbCellera already have enabled three of the firm’s stealth-stage companies under previous partnerships. Under the terms of the deal, Versant portfolio companies will have rights to develop and commercialize the resulting therapeutic antibodies. AbCellera will receive resear...

Read More
news image

CELL AND GENE THERAPY

INTRAVACC ANNOUNCES ADDITIONAL FAVORABLE PRECLINICAL AND TOXICOLOGY DATA FOR AVACC 10®, AN INTRANASAL SARS-COV-2 CANDIDATE VACCINE

Intravacc | September 12, 2022

Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced additional favorable preclinical and toxicology data for Avacc 10®, the company's SARS-CoV-2 intranasal candidate vaccine. These results demonstrate a reduction in upper respiratory tract viral load, broad cross protection against circulating variants of concern. and a good safety profile, allowing progression towards a phase I clinical study. ...

Read More